Thermo Fisher Scientific Inc. has completed its acquisition of PPD, Inc., a global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion.
 
“We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD’s leading clinical research services advances our work in bringing life-changing therapies to market, benefitting patients around the world.”
 
With the addition of PPD, Thermo Fisher will offer a comprehensive suite of services across the clinical development spectrum − from scientific discovery, to assessing safety, efficacy, and health care outcomes, to managing clinical trial logistics, to the development and manufacturing of the drug product.